ELDN Eledon Pharmaceuticals Inc
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The firm’s compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. The CD40L/CD40 pathway is recognized for its prominent role in immune regulation, making it a candidate for therapeutic intervention in transplant tolerance, autoimmune disease, and neuro-inflammation. The company is building upon a deep historical understanding of the CD40/CD40L pathway, as well as preclinical and Phase 1 data, to initiate up to four phase 2 clinical studies with AT-1501. The company was founded on March 26, 2004 and is headquartered in Irvine, CA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
31
Frequently Asked Questions
What is Market Cap of Eledon Pharmaceuticals Inc?
What is the 52-week high for Eledon Pharmaceuticals Inc?
What is the 52-week low for Eledon Pharmaceuticals Inc?
What is Eledon Pharmaceuticals Inc stock price today?
What was Eledon Pharmaceuticals Inc stock price yesterday?
What is the PE ratio of Eledon Pharmaceuticals Inc?
What is the Price-to-Book ratio of Eledon Pharmaceuticals Inc?
What is the 50-day moving average of Eledon Pharmaceuticals Inc?
How many employess does Eledon Pharmaceuticals Inc has?